Let's get more solutions to patients faster! Partnering with a Venture Capitalist (VC) may fast forward your innovation, because they could bring much more to the table than just funding.
During this session you can learn more about the instrumental role VCs can play in your start-up company’s plans, the innovation ecosystem and how collaborating with them may accelerate potential breakthrough solutions to significant healthcare challenges the world faces today. Are you ready to gain valuable insights and connect with a potential partner?
On 24 June 2020 BioGeneration Ventures announced1 they closed their BGV IV fund of €105 million. The investments will focus on entrepreneurial innovation in therapeutics in Europe. During this webinarEdward van Wezel, Managing Partner of BioGeneration Ventures, will elaborates on the firm's aim to build new companies around either single assets or technology platforms with the goal of creating transformational new medicines.
BioGeneration Ventures is one of the largest VC funds in Europe focused on early investments in new bio-technology companies, with over €220 million assets under management.2 Its team has broad experience in investment, life sciences, business development, and commercial operations. It also draws on experienced biotech entrepreneurs as venture partners and advisors, to the benefit of its portfolio companies.
BioGeneration Ventures is seeking:
- Direct investment or co-development partnership opportunities with European life sciences companies with (pre)clinical therapeutic assets or platform technologies up to and including series B financing;
- Collaborations with academic researchers to advance and translate their innovative early-stage therapeutic assets into new products and companies of scale.
[1] Source: https://www.biogenerationventures.com/news-releases/biogeneration-ventures-closes-bgv-iv-fund-at-e105-million/
[2] Source: https://www.biogenerationventures.com/fund/
Edward currently serves on the supervisory boards of Progentix Orthobiology, Cristal Therapeutics, Synaffix, Staten Biotechnology, Escalier BioSciences and Scenic Biotech. He served on the supervisory boards of BioCeros (sold in 2011), Noviogendix (acquired by MDxHealth) and was founding investor and supervisory board member of Acerta Pharma (acquired by Astra Zeneca). Edward is also on the board of Mibiton.
Edward started his career as process engineer for Chiron Inc.. He subsequently worked in product development and corporate licensing at Johnson & Johnson. Since 2000 he expanded his experience as CEO of several life sciences companies in the Netherlands.
Edward holds a M.Sc. in chemistry from the University of Utrecht and a M.Sc in Biochemical Engineering from the Delft University of Technology.
Johnson & Johnson Innovation – JLABS Notice
The information in this event is for informational purposes only. The information is either proprietary or licensed to Johnson & Johnson Innovation LLC, its parent company or any affiliate companies ("JJI") or is provided by or proprietary to third parties. In case of third party information, please note that only those third parties that provided or own this information are responsible for it. By providing this information, JJI is not affiliated with nor endorses these third parties or any of the information provided in this event. This content is not intended to influence the use, sale, recommendation, or promotion of any products or services of JJI, Johnson & Johnson or its affiliates. JJI and Johnson & Johnson are not responsible or liable for any actions you do or do not take in relation to this information and are not responsible for any use of this information by you. By providing the information in this event, JJI does not make any representations, warranties, or assurances, express or implied, as to the content or the information presented in thisevent and is not responsible for any use by or alterations of this information by you. JJI hereby expressly disclaims any and all guarantees, representations, warranties, or assurances and assumes no responsibility or liability, direct or indirect in relation to the information in this event.
